Speaker illustration

Associate Professor Stanko Skrtic

Soborg (Sweden)

Initial clinical experience with AZD5718, a novel once daily oral 5-lipoxygenase activating protein (FLAP) inhibitor, intended for patients with coronary artery disease

Event: ESC Congress 2017

Topic: Drug therapy

Session: Best Posters in new targets in cardiovascular drug assessment

Thumbnail

ESC 365 is supported by